Dallas, TX — April 30, 2025 (GLOBE NEWSWIRE) — Spark Biomedical, a pioneering leader in wearable neurostimulation technology, announced today the successful closing of its $15 million Series A funding round. The round was led by WAVE Ventures, with strategic participation from Pathway to Cures, the venture philanthropy fund of the National Bleeding Disorders Foundation.
This milestone investment will accelerate Spark Biomedical’s mission to transform patient care through bioelectronic medicine, with a focused expansion in neurological health, hemostasis, and women’s health.
Advancing a New Standard in Non-Invasive, Drug-Free Therapies:
Spark Biomedical is at the forefront of a healthcare revolution, harnessing the body’s natural electrical systems to deliver precise, targeted neurostimulation therapies — without the need for pharmaceuticals or invasive surgical procedures. Using mild, non-invasive electrical pulses to stimulate key nerves such as the vagus and trigeminal nerves, Spark’s wearable devices activate the body’s central nervous system to relieve symptoms, modulate biological pathways, and restore physiological balance.
“Completing our Series A fundraise marks a pivotal moment for Spark Biomedical as we scale our bioelectronic medicine platform,” said Daniel Powell, CEO and Co-founder of Spark Biomedical. “This capital empowers us to expand clinical applications for neurostimulation therapies and bring life-changing, drug-free solutions to areas of significant unmet clinical need.”
Strategic Backing from Industry Leaders:
The Series A round was led by WAVE Ventures, a venture capital firm focused on supporting breakthrough healthcare and biotechnology ventures.
Allen Page, Managing Partner at WAVE Ventures, commented:
“We’re proud to back Spark Biomedical in its mission to deliver transformative, non-invasive therapies. From behavioral health to women’s health, Spark is tackling some of healthcare’s most pressing challenges and offering better, drug-free alternatives for patients.”
Joining WAVE Ventures in the round is Pathway to Cures, a strategic venture philanthropy fund dedicated to supporting companies developing cures and therapies for the inheritable blood and bleeding disorders community, backed by the National Bleeding Disorders Foundation. This investment will help advance Spark’s hemostasis-focused bioelectronic treatments and expand applications for bleeding disorders care.
Clinical Innovation with a Purpose:
It has established itself as a trailblazer in wearable bioelectronic medicine, with a robust pipeline of clinical and engineering programs designed to address conditions where current pharmaceutical options fall short or bring unwanted side effects. Its technology platform has already demonstrated promising outcomes in areas such as:
Postoperative pain management
Pediatric neuromodulation
Hemostasis and bleeding control
Its wearable neurostimulation solutions are built on science-backed evidence and developed in partnership with leading medical institutions, federal agencies like the NIH and U.S. Department of Defense, and academic research organizations.
About Spark Biomedical:
Spark Biomedical, Inc. is a Dallas-based medical device innovator focused on unlocking the potential of bioelectronic medicine. The company develops novel, wearable neurostimulation treatment options that address unmet needs in behavioral health, women’s health, pediatrics, hemostasis, and chronic pain management.
By combining neuroscience expertise with cutting-edge engineering, Spark Biomedical empowers healthcare providers and researchers with evidence-based tools designed for complex clinical challenges where conventional treatments may fall short. The company’s technology has received funding and validation from prominent federal and academic institutions, as well as leading private sector partners.
For more information, visit sparkbiomedical.com.
For more insights and updates on Metaverse, DeFi, Blockchain, NFT & Web3, be sure to subscribe to our newsletter. Stay informed on the latest trends and developments in the decentralized world.
